Treatment of overactive bladder: A model comparing extended-release formulations of tolterodine and oxybutynin

American Journal of Managed Care

Volumn 11, Issue SUPPL. 4, 2005, Pages

  Perfetto, Eleanor M ^a   Subedi, Prasun ^a   Jumadilova, Zhanna ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN; TOLTERODINE;

ARTICLE; COHORT ANALYSIS; DRUG COST; DRUG FORMULATION; DRUG RELEASE; FOLLOW UP; HEALTH CARE COST; HUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; REIMBURSEMENT; SENSITIVITY ANALYSIS;

AGED; BENZHYDRYL COMPOUNDS; COHORT STUDIES; CRESOLS; DELAYED-ACTION PREPARATIONS; HEALTH CARE COSTS; HUMANS; MANDELIC ACIDS; MODELS, THEORETICAL; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; UNITED STATES; URINARY INCONTINENCE;

EID: 22544477830     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327-336.
2. Hu TW, Wagner TH, Bertkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61:1123-1128.
3. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87: 760-766.
4. Zhou Z, Jensen GA. Insurance claims costs for overactive bladder disorder. Drug Benefit Trends. 2001; 13:45-58.
5. Muchmore L, Williamson TE, Gardner H. Incidence and cost associated with pharmacological treatment for employees diagnosed with urinary and overactive bladder disorders. Value Health. 2002;5:275-276.
6. Bailey KL, Torigoe YR, Zhou S, et al. Overactive bladder cost of illness: analysis of Medi-Cal claims. Value Health. 2000;3:139-140.
7. Arikian SR, Casciano J, Doyle JJ, Tarride JE, Casciano RN. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface. 2000;13:88-94.
8. Becker RV, Noe LL, Trotter JP, et al. A cost-effectiveness comparison of extended release tolterodine (Detrol® LA) versus controlled release oxybutynin (Ditropan® XL). Poster presented at: 80th Annual Meeting of the South Central Section of the American Urological Association; September 12, 2001; Austin, Tex. Poster 236.
9. Bentkover J, Bachleda M, Kulseng-Hansen S, et al. An economic model of overactive bladder in Norway. Value Health. 2002;5:275.
10. Chapple C, Hill S, Corey R, et al. An economic model of unstable bladder in the United Kingdom. Poster presented at: Second International Consultation on Incontinence; July 1-3, 2001; Paris, France. Poster 77.
11. Kobelt G, Johnson L, Mattiasson A. Cost effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodynam. 1998;17:599-611.
12. Getsios D, Caro JJ, Ishak KJ, El-Hadi W, Payne K. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin Ther. 2004;26: 431-438.
13. O'Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T. Cost-effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther. 2001;23:2038-2049.
14. Noe L, Becker R, Williamson T, Chen D. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm. 2002;8:343-352.
15. Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for management of urge incontinence. Pharmacoeconomics. 2004;22:1047-1059.
16. PharMetrics. Pfizer OAB Draft Technical Report. On file, 2004.
17. AnalySource. AnalySource Online. Available at: http://www.analysource. com. Accessed December 2004.
18. PharMetrics. Overview. Available at: http://www. pharmetrics.com/ h_overview.html. Accessed February 24, 2005.
19. Chiaffarino F, Parazzini F, Lavezzari M, et al. Impact of urinary incontinence and overactive bladder on quality of life. Eur Urol. 2003;43:535-538.